AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

To join this study, you would need to have been recently diagnosed with glioblastoma and meet certain health requirements. This means your doctors would have confirmed your diagnosis, and if you had surgery, it was either a biopsy or a partial removal of the tumour. You should generally be in good health, able to look after yourself, and be between 18 and 75 years old.

There are also specific health checks that need to be met, such as having healthy blood cell counts (like enough platelets and white blood cells) and your kidneys and liver working well. If you're taking steroid medication, the dose needs to have been steady or reducing for at least two weeks before you start. You also need to be able to take medicines by mouth.

However, you wouldn't be able to join if you've already had brain radiotherapy or certain chemotherapy treatments for your cancer. Other reasons you might not be able to join include having certain gut problems, severe diarrhoea, or if you're currently in another medical trial. Also, if you've had another type of cancer in the last five years (except for some very common skin cancers), you might not be eligible. Women who could become pregnant would need to have a negative pregnancy test and agree to use effective birth control during and after the trial.

If you decide to take part, you'll receive the AGuIX nanoparticles through a drip into your arm, along with your regular radiotherapy and Temozolomide medication. The AGuIX will be given at a specific dose determined in the study.

You will have several visits to the hospital for treatments, blood tests, and check-ups to see how you are responding and to monitor for any side effects. These assessments will involve speaking with the study doctor and nurses, and possibly having scans or other tests. The exact number and frequency of visits will be explained to you, but typically, clinical trials involve regular monitoring during the treatment period and then follow-up appointments afterwards. The total duration someone is in the study will vary, but it will involve a treatment phase and then a period where you are monitored after treatment ends.